Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA...
-
AUSTIN, Texas, Oct. 07, 2025 (GLOBE NEWSWIRE) -- NAPEO -- A new report from isolved®, 2025 Service Bureau Insights : How PEOs, ASOs and Payroll Providers Are Evolving in the AI Era, reveals that the...
-
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
-
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
-
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
-
Open Letter to Shareholders
-
TransCode Therapeutics Announces Nasdaq Extension to Re-gain Compliance
-
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review o
-
TransCode Therapeutics Completes Initial Dosing of First Co-hort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
-
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate